Sector Expert: Ram Selvaraju

Rodman & Renshaw

Image: Ram Selvaraju

Raghuram "Ram" Selvaraju's professional career started at the Geneva-based biotech firm Serono in 2000, where he discovered the first novel protein candidate developed entirely within the company. He subsequently became the youngest recipient of the company's Inventorship Award for Exceptional Innovation and Creativity. Selvaraju started in the securities industry with Rodman & Renshaw as a biotechnology equity research analyst. He was the top-ranked (#1) biotech analyst in The Wall Street Journal's "Best on the Street" survey (2006) and went on to become head of healthcare equity research at Hapoalim Securities, the New York-based broker/dealer subsidiary of Bank Hapoalim B. M., Israel's largest financial services group. While at Hapoalim, Selvaraju was regularly featured in The Wall Street Journal, Barron's, BioWorld Today, and Reuters/AP. He was also a regular guest on the Bloomberg TV program "Taking Stock," appeared with Bloomberg TV's on-air correspondents Betty Liu and Gigi Stone and was a guest on CNBC's "Street Signs with Herb Greenberg."



Recent Interviews

2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market (4/19/17)
2017_watchlist

The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year.

2017 Small-Cap Biotech Watchlist: Takeaways for Investors (1/18/17)
2017_watchlist

Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11.

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist (1/3/17)
2017_watchlist

Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January.

Recent Quotes

"VGX-3100 is the first candidate within INO's extensive pipeline to enter a pivotal study, and is the first immunotherapy and non-surgical treatment for high-grade squamous intraepithelial lesions."

— Ram Selvaraju, H.C. Wainwright & Co. (6/8/17)
moreá>

"INO announced the second collaboration study involving the companyĺs INO-5401 T-cell activating immunotherapy."

— Ram Selvaraju, H.C. Wainwright & Co. (6/2/17)
moreá>

"INO's early results are very encouraging but not surprising, as they are in line with results from the company's trials of other DNA vaccines."

— Ram Selvaraju, H.C. Wainwright & Co. (5/25/17)
moreá>

"INO has submitted a complete response to the FDA, which includes extensive testing and validation data of its Cellectra 5PSP delivery device developed for the Phase 3 study and future commercial use."

— Ram Selvaraju, H.C. Wainwright & Co. (5/11/17)
moreá>

"We note that INO's VGX-3100 would be the first candidate within the company's extensive pipeline to enter a pivotal study."

— Ram Selvaraju, H.C. Wainwright & Co. (3/16/17)
moreá>

"INO's preliminary data show immune responses in 100% of Zika-vaccinated and 98% of MERS-vaccinated human subjects."

— Ram Selvaraju, H.C. Wainwright & Co. (2/24/17)
moreá>

"INO announced that its DNA-based Zika vaccine (GLS-5700) had generated robust antigen-specific antibody responses in healthy adult volunteers in a multi-center first-in-human Phase 1 trial."

— Ram Selvaraju, H.C. Wainwright & Co. (12/22/16)
moreá>

"INO plans to have three drug candidates ready for registration in 2020."

— Ram Selvaraju, H.C. Wainwright & Co. (11/10/16)
moreá>

more comments

"DRRX's DUR-928 could demonstrate more pronounced efficacy at a higher dose with a benign safety profile in the ongoing and future trials."

— Ram Selvaraju, Rodman & Renshaw (11/1/16)
moreá>

"INO's clincial hold does not change our overall view on the efficacy and safety of VGX-3100 in treating high grade cervical dysplasia, nor does it have a meaningful impact on our valuation of the product."

— Ram Selvaraju, H.C. Wainwright & Co. (10/25/16)
moreá>

"We continue to expect positive readouts from DRRX's DUR-928 trials considering the drugĺs multiple levels of mechanism of action."

— Ram Selvaraju, Rodman & Renshaw (9/27/16)
moreá>

"INO announced that it has initiated a second clinical study of its preventive Zika vaccine, GLS-5700, in Puerto Rico."

— Ram Selvaraju, H.C. Wainwright & Co. (8/29/16)
moreá>

"The FDA and the EMA have provided an affirmative path for INO's VGX-3100 to treat cervical dysplasia in a pivotal Phase 3 registration study; this is encouraging news."

— Ram Selvaraju, Rodman & Renshaw (8/9/16)
moreá>

"We continue to expect a positive outcome from DRRX's pivotal study for Posimir."

— Ram Selvaraju, Rodman & Renshaw (8/2/16)
moreá>

"DRRX's REMOXY is likely to secure regulatory approval in September."

— Ram Selvaraju, Rodman & Renshaw (7/5/16)
moreá>

"INO has sufficient capital to finish the study, and management expects to report results from the Phase 1 trial by the end of 2016."

— Ram Selvaraju, H.C. Wainwright & Co. (6/21/16)
moreá>

"INO is on track to commence the VGX-3100 Phase 3 study in 2016; we reiterate our Buy rating."

— Ram Selvaraju, H.C. Wainwright & Co. (5/10/16)
moreá>

"We expect positive readouts from DRRX's DUR-928 and the POSIMIR studies."

— Ram Selvaraju, Rodman & Renshaw (5/9/16)
moreá>

"We are initiating coverage on DRRX with a Buy rating."

— Ram Selvaraju, Rodman & Renshaw (4/25/16)
moreá>

"INO expects to initiate human trials of its Zika virus vaccine by the end of 2016."

— Ram Selvaraju, H.C. Wainwright & Co. (4/8/16)
moreá>

"INO's cervical dysplasia Phase 3 trial is to initiate in early Q3/16."

— Ram Selvaraju, H.C. Wainwright & Co. (3/16/16)
moreá>

"CYP signed an agreement with Regience to co-commercialize Cymerus."

— Ram Selvaraju, Rodman & Renshaw (3/4/16)
moreá>

"The Neutrolin platform positions CRMD particularly well going forward."

The Life Sciences Interview with Ram Selvaraju (2/10/16)
moreá>

"CYP has the only truly sustainable production platform for MSCs."

The Life Sciences Interview with Ram Selvaraju (2/10/16)
moreá>

"ATHX is getting a $15M upfront cash payment as part of its agreement with Tokyo-based big pharma Healios."

The Life Sciences Interview with Ram Selvaraju (2/10/16)
moreá>

"CYP received favorable clinical testing advice from the MHRA."

— Ram Selvaraju, Rodman & Renshaw (1/28/16)
moreá>

"CRMD has one of the few programs that deals conclusively with multidrug-resistant bacterial infections."

The Life Sciences Report Interview with Ram Selvaraju (1/27/16)
moreá>

"We should see SRNE's first investigational new drug (IND) application filed in 2016; there is enough evidence for investors to be intrigued."

The Life Sciences Report Interview with Ram Selvaraju (1/6/16)
moreá>

"INO generated very positive and encouraging clinical data from a Phase 2b trial of VGX-3100."

The Life Sciences Report Interview with Ram Selvaraju (1/6/16)
moreá>

"CRMD currently trades at a significant discount to peer publicly traded, single-product, anti-infective firms."

The Life Sciences Report Interview with Ram Selvaraju (12/15/15)
moreá>

"We initiate coverage of CYP with a Buy rating."

— Ram Selvaraju, Rodman & Renshaw (12/7/15)
moreá>

"We are initiating coverage of CRMD with a Buy rating."

— Ram Selvaraju, H.C. Wainwright & Co. (11/12/15)
moreá>

fewer comments


Due to permission requirements, not all quotes are shown.